PMC9510372_01
Treatment flowchart and timeline of symptoms. Abbreviations: HR+HSCT, high risk block chemotherapy with hematopoietic stem cell transplantation; IR-High, intermediate-high risk group; MRD, minimal residual disease; TKI, tyrosine kinase inhibitor; TP1, time point 1: end of Induction, day 29; TP2, time point 2: end of Consolidation 1, day 71.
pore-28-1610570-g001.jpg
PMC9510372_01_pore-28-1610570-g001.jpg
F1
Discrepancy in the lab results was interpreted as a subclone of leukemic cells that was not captured by PCR, and the patient was stratified to intermediate-high risk (IR-H) due to a slow response to the therapy as per protocol (Figure 1). The patient was stratified into High-Risk (HR) group with allogeneic hematopoietic stem cell transplantation (allo-HSCT) (Figure 1). Complete remission (CR) was achieved within a month, and treatment was downgraded to intermediate-risk protocol (Figure 1).